Latest News

Learn about a new FDA-approved long-term glaucoma treatment, the benefits and risks of glaucoma surgery, research exploring how pressure in the eye is regulated, risk factors for the development of glaucoma, and more in the fall edition of Natonal Glaucoma Research Report.

In animal experiments, scientists document that the APOE4 allele impacts cell bioenergetics in the entorhinal cortex, a critical brain region first damaged in Alzheimer’s disease (AD).

Scientists describe how the protein tau is modified over four decades as Alzheimer’s develops and progresses.

New partnerships with BrightFocus Foundation and CURE will promote research, clinical trials in neurology practices nationwide

BrightFocus Foundation mourns the recent passing of Peter Davies, PhD. A globally-recognized leader in research on Alzheimer’s and related dementia, Dr. Davies served on our Scientific Review Committee for this field for 11 years, including six years as its chair.

In partnership with BrightFocus Foundation, the Medical Technology Enterprise Consortium (MTEC) today announced a request for proposals for research that will enable the advancement of candidate drugs for the treatment of repeated mild traumatic brain injury (mTBI).

Inhibiting thyroid hormone (TH) activity helps protect against retinal degeneration in an animal model of AMD.

BrightFocus Foundation, a premier private funder of vision research, today announced a request for proposals for science projects supported through its National Glaucoma Research program.

Researchers unravel the reasons why some patients have no response or diminished response over time to anti-VEGF [vascular endothelial growth factor) drugs used to treat age-related macular degeneration (AMD) and discover an innovative and effective combination therapy.